Real-Life Effectiveness and Safety of Sofosbuvir-Based Therapy in Genotype 2 Chronic Hepatitis C Patients in South Korea, with Emphasis on the Ribavirin Dose.
Eun Sun JangKyung-Ah KimYoung Seok KimIn Hee KimByung Seok LeeYoun Jae LeeWoo Jin ChungSook-Hyang JeongPublished in: Gut and liver (2021)
SOF-based therapy showed high real-life efficacy and tolerability in Korean patients with genotype 2 chronic HCV infection, regardless of previous antiviral treatment experience and fibrosis score. A reduced ribavirin dose can be considered in this patient cohort.
Keyphrases
- hepatitis c virus
- end stage renal disease
- newly diagnosed
- ejection fraction
- chronic kidney disease
- peritoneal dialysis
- case report
- prognostic factors
- open label
- randomized controlled trial
- clinical trial
- human immunodeficiency virus
- liver fibrosis
- patient reported outcomes
- mesenchymal stem cells
- study protocol
- drug induced
- placebo controlled